• Active, not recruiting

NCT02874742 : Phase 2 - Daratumumab, Len., Bortezomib & Dex (D-RVd) Vs (RVd) in New MM - GRIFFIN

Updated: Oct 24

The GRIFFIN trial


Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Griffin Clinical Trial

The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the International Myeloma Working Group (IMWG) criteria, by the time of completion of post autologous stem cell transplantation (ASCT) consolidation treatment, compared with RVd alone.


Sponsor

Janssen Research & Development, LLC

 

ClinicalTrials.gov Identifier: NCT02874742

Official Title: Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation

First Posted : August 22, 2016

Click here for details on ClinicalTrials.gov

 

Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information


Bortezomib : National Cancer Institute

Bortezomib : MedlinePlus Drug Information

Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

 

Patient Information - FDA Approved Drugs Multiple Myeloma

Drugs | Myeloma Clinical Trials (themyelomaclinicaltrials.com)

 

Drug: Lenalidomide (Revlimid)

Drug: Bortezomib (Velcade)

Drug: Dexamethasone (Decadron)

Drug: Daratumumab (Darzalex)

 

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Blood; August 2020

Click here for details

 

549 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Initial Therapy

Hematology Disease Topics & Pathways:

multiple myeloma, Biological, antibodies, Adult, Diseases, Therapies, Plasma Cell Disorders, Lymphoid Malignancies, Study Population

Monday, December 7, 2020: 7:15 AM

Learn more

 

Blood Adv; Feb 2021

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

Learn more

 

RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.

Click here for details

 

79 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Phase 2 and 3 Trials in Myeloma

Hematology Disease Topics & Pathways:

Clinical Trials, Biological, Adults, Clinical Research, Plasma Cell Disorders, Diseases, Therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy, Study Population

Saturday, December 11, 2021: 9:30 AM

Learn more

 

Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.

2022 ASCO Annual Meeting

June 02, 2022

Click here for details

 

Post Hoc Analysis of Sustained MRD Negativity (GRIFFIN Trial) in TE NDMM Patients - YouTube

June 28, 2022

International Myeloma Foundation

Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma

 

OAB-057 Daratumumab (DARA) + Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of GRIFFIN -Douglas Sborov


#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California

IMS 2022 Abstract EBook

https://www.myelomasociety.org/


#IMS2022 - 19th International Myeloma Society Annual Meeting; Aug 25-27, LA California (themyelomaclinicaltrials.com)

 

- Multiple locations


- Alabama: University of Alabama at Birmingham

- California: City of Hope Duarte

- Georgia: Emory University Atlanta

- Illinois: University of Chicago

- Florida: Moffitt Cancer Center Tampa

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Missouri: Washington University School of Medicine Saint Louis

- Nebraska: University of Nebraska Medical Center Omaha

- North Carolina: Levine Cancer Institute Charlotte

- North Carolina: Wake Forest Baptist Health Winston-Salem

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- Texas: UT Southwestern Medical Center Dallas

- Texas: The University of Texas MD Anderson Cancer Center Houston

 

Locations

United States, Alabama

United States, California

United States, Colorado

United States, District of Columbia

United States, Florida

United States, Georgia

United States, Illinois

United States, Kansas

United States, Louisiana

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, Missouri

United States, Nebraska

United States, New York

United States, North Carolina

United States, Ohio

United States, Oregon

United States, Pennsylvania

United States, Tennessee

United States, Texas

United States, Utah

United States, Washington

United States, Wisconsin

 

RELATED POSTS


NCT03710603: Phase 3 (Perseus) EMN17 - Dara-VRd Vs VRd - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM

Click here for details


NCT03652064: Phase 3 (CEPHEUS) MMY3019 - Dara-VRd Vs VRd - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM

Click here for details


NCT04566328: Phase 3 (EQUATE) - EAA181 - Dara-VRd Vs Dara-Rd - Testing the Use of Combination Therapy in NDMM

Click here for details


NCT02195479: Phase 3 (ALCYONE) Dara-VMP Vs VMP - Bortezomib, Melphalan, Prednisone & Daratumumab

Click here for details


NCT02541383: Phase 3 (CASSIOPEIA) Dara-VTd Vs VTd - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT

Click here for details


NCT04268498: Phase2 (ADVANCE) Dara-KRd - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma

Click here for details


NCT03290950: Phase 2 (Manhattan) Dara-KRd - A Study of Daratumumab in Patients With NDMM wKRd-D

Click here for details


NCT02252172: Phase 3 (MAIA) Dara-Rd Vs Rd - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma

Click here for details


NCT03729804: Phase 3 (COBRA) - KRd Vs VRd in Patients with Newly Diagnosed Multiple Myeloma

Click here for details


NCT04096066: Phase 3 KRd Vs Rd - A Trial That Compare Two Treatments TIE - NDMM

Click here for details


NCT01402284: Phase 2 - KRd - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

Click here for details

 

NCT04483739: Phase 3 (Iskia) - Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Eligible for ASCT

Click here for details


NCT03319667: Phase 3 (IMROZ) - Isa-VRd Vs VRd - Isatuximab, Bortezomib, Lenalidomide and Dex NDMM

Click here for details


NCT04751877: Phase 3 (IFM2020-05) - Isa-VRd Vs Isa-Rd - Non-Frail NTE Myeloma Elderly Patients

Click here for details

 

NCT04923893: Phase 3 (CARTITUDE-5) VRd --> Cilta-cel Vs VRd --> Rd - NDMM- (No ASCT planned)

Click here for details


NCT05257083: Phase 3 (CARTITUDE-6) DVRd -> Ciltacabtagene Autoleucel Vs DVRd -> Transplant ASCT- NDMM

Click here for details

 

NCT01850524: Phase 3 (TOURMALINE-MM2) Ixa-Rd Vs Rd - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM

Click here for details





Posts Archive